Vogenx names board member Richard Gorman as Chief Commercial Officer
Gorman will resign from the Vogenx board effective October 12, 2026 as he moves into the newly created commercial role.
Vogenx, Inc. (Nasdaq: VOGX) announced on October 9, 2026 that Richard "Rich" Gorman will join the Vogenx management team as Chief Commercial Officer, effective October 12, 2026.1 Gorman has served on the Vogenx board since 2022, and concurrent with his joining the management team, he will resign as a member of the Board and its committees.1 According to the company's 8-K, his resignation covers all committees on which he served, including the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026.1 The filing states his resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.1 Vogenx said it will conduct a search to identify a new independent director to join the Board.1
In the newly created role, Mr. Gorman will lead commercial operations and corporate strategy for Vogenx, including market development for post-bariatric hypoglycemia (PBH), gastroparesis, and long-range portfolio planning across the Company's pipeline, and will initially also be responsible for business development activities, including partnering and licensing strategy.1
The release describes Gorman as a 30-year commercial leader in the life sciences industry who has supported more than 25 product launches in the U.S. and international markets, including rare disease and specialty products, with peak sales ranging from $350 million to more than $3 billion.1 Most recently, he served as President, Life Science Commercialization and Strategic Consulting at Envision, where he led strategic consulting for launch readiness, health economics and pricing strategy for emerging biopharma companies bringing their first product to market.1
Vogenx is developing mizagliflozin, its lead candidate, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome.1 The company noted its development work relies in part on the Company's license from Kissei Pharmaceutical Co., Ltd.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.